Background Rho kinases (ROCKs) contribute to allergic airways disease. ROCKs also play a role in lymphocyte proliferation and migration. + cells from OT-II mice restored effects of OVA on lymphocytes, eosinophils, IL-13, IL-5, and mucous hypersecretion to wild-type levels, whereas eotaxin and airway hyperresponsiveness were not affected. ROCK2 inhibitors reduced IL-13-induced release of eotaxin from airway smooth muscle (ASM), similar to effects of these inhibitors on ASM contractility. Despite the ability of adoptive transfer to restore allergic airways inflammation in ROCK2-insufficient mice, allergic inflammation was not different in ROCK2 CD4Cre vs. control mice. Conclusion ROCK2 contributes to allergic airways responses likely via effects within ASM cells and within non-lymphocyte cells involved in lymphocyte activation and migration into the airways.
Summary
Background Rho kinases (ROCKs) contribute to allergic airways disease. ROCKs also play a role in lymphocyte proliferation and migration. Objective To determine the role of ROCK2 acting within CD4
+ cells in allergic airways responses. Methods ROCK2-haploinsufficient (ROCK2 +/À ) and wild-type mice were sensitized with ovalbumin (OVA). ROCK2 +/À mice then received either CD4 + cells from ROCK2-sufficient OVA TCR transgenic (OT-II) mice or saline i.v. 48 h before challenge with aerosolized OVA. Wild-type mice received saline before challenge. Allergic airways responses were measured 48 h after the last challenge. Allergic airways responses were also assessed in mice lacking ROCK2 only in CD4 + cells (ROCK2 CD4Cre mice) vs. control (CD4-Cre and ROCK2 flox/flox ) mice. Results OVA-induced increases in bronchoalveolar lavage lymphocytes, eosinophils, IL-13, IL-5, and eotaxin were reduced in ROCK2 +/À vs. wild-type mice, as were airway hyperresponsiveness and mucous hypersecretion. In ROCK2 +/À mice, adoptive transfer with CD4
+ cells from OT-II mice restored effects of OVA on lymphocytes, eosinophils, IL-13, IL-5, and mucous hypersecretion to wild-type levels, whereas eotaxin and airway hyperresponsiveness were not affected. ROCK2 inhibitors reduced IL-13-induced release of eotaxin from airway smooth muscle (ASM), similar to effects of these inhibitors on ASM contractility. Despite the ability of adoptive transfer to restore allergic airways inflammation in ROCK2-insufficient mice, allergic inflammation was not different in ROCK2
Introduction
The Rho-associated coiled-coil forming kinases (ROCKs) are serine/threonine kinases that are targets of the Rho family of small GTP-binding proteins [1, 2] . Multiple lines of evidence support the hypothesis that ROCK proteins are involved in the pathogenesis of allergic asthma. Airway narrowing caused by airway smooth muscle (ASM) contraction is a canonical feature of asthma, and ROCKs participate in smooth muscle contraction via their ability to inhibit myosin light chain phosphatase (MLCP) [3] [4] [5] . ROCKs can also participate in cell migration, including the migration of T lymphocytes and eosinophils [6] [7] [8] [9] , cells that infiltrate the airways in allergic asthma. ROCKs are activated by GTP binding to RhoA, and RhoA expression increases in bronchi of allergen-sensitized and challenged rats and guinea-pigs [10, 11] . Furthermore, many of the inflammatory mediators released upon allergen challenge are capable of activating RhoA [12] . Indeed, in ovalbumin (OVA)-sensitized mice, OVA aerosol challenge results in ROCK activation in the lungs that peaks about 4 h post-challenge and resolves over the next 48 h [13] . Importantly, the ROCK inhibitors, Y27632 and fasudil, attenuate airway hyperresponsiveness (AHR), eosinophilic airway inflammation, Th2 cytokine expression, and mucous hypersecretion in lungs of OVA-sensitized and challenged animals [14] [15] [16] [17] . Similarly, ROCK-insufficient mice also have reduced responses to allergen challenge [13] . However, the cell types in which ROCK acts to induce these effects have not been established.
Actions of ROCK within Th2 lymphocytes could account for the observed reductions in allergic airways responses after ROCK inhibition or in animals with ROCK insufficiency. In allergen-sensitized and challenged mice, the type 2 cytokine, IL-13, is required for AHR, airway eosinophilia, and mucous cell hyperplasia [18, 19] , and ROCK inhibitors reduce pulmonary expression of IL-13 after allergen sensitization and challenge [17] . Inhibiting ROCK also prevents lymphocyte chemotaxis induced by SDF-1, CCL19, and CCL20 [20] [21] [22] and lymphocyte proliferation induced by concanavalin A or anti-CD3 [23] . Likewise, in co-cultures of dendritic cells with T lymphocytes from mice that are transgenic for a T cell receptor (TCR) that recognizes OVA peptide (OT-II mice), ROCK inhibition decreases the lymphocyte proliferation observed upon the addition of OVA [13] . ROCK inhibitors also inhibit cytokine release by peripheral blood T cells stimulated with ConA [24] .
Two ROCK isoforms have been identified: ROCK1 and ROCK2 [25, 26] . The two isoforms have similar, but not identical substrate specificities. There are also differences in their cellular expression, their intracellular localization, and their regulation [25, [27] [28] [29] [30] [31] . These differences suggest that ROCK1 and ROCK2 may have non-redundant functions in regulating airway responses. Indeed, ROCK2 +/À mice have reduced allergic airways responses even when ROCK1 is fully functional, indicating that ROCK2 has a role not fulfilled by ROCK1 [13] . Similarly, ROCK2 does not compensate for loss of ROCK1 [13] : ROCK1 +/À mice have reduced allergic airways responses even when ROCK2 is fully functional. Here, we focused on the role of ROCK2.
The purpose of this study was to examine the hypothesis that ROCK2 activation within lymphocytes contributes to allergen-induced AHR, eosinophilia, and mucous cell hyperplasia. Most ROCK2 À/À mice die either in gestation or early post-natally [32] . However, ROCK2 +/À mice are viable. Lungs and other tissues from ROCK2 +/À mice express about 50% of wild-type ROCK2 levels without changes in ROCK1 [13, 33] . We assessed allergic airways responses in WT and ROCK2 +/À mice that had been sensitized with OVA and challenged with either PBS or OVA aerosol. To examine the role of ROCK2 within lymphocytes, prior to OVA aerosol challenge ROCK2 +/À mice were administered (i.v.) either saline or splenic T lymphocytes derived from OT-II mice. We reasoned that if the reduced allergic airways responses observed in ROCK2 +/À mice were the result of loss of lymphocytes in the airways consequent to the effects of ROCK2 in lymphocyte migration, proliferation, or cytokine production, then these functional deficits would be overcome if we provided ROCK2-sufficient lymphocytes that could respond to OVA. In contrast, if the role of ROCK2 was primarily the result of its actions in other cell types, no change in allergic airways responses would occur even if ROCK2 +/À mice were provided with ROCK2-sufficient lymphocytes. We also crossed ROCK2-floxed mice (ROCK2 flox/flox ) [34] with mice expressing Cre recombinase under the influence of a CD4 promoter (CD4-Cre mice) to generate mice that lacked ROCK2 only in CD4 cells (ROCK2 CD4Cre ). Allergic airways responses were then assessed in ROCK2 CD4Cre mice and their controls (ROCK2 flox/flox and CD4-Cre mice).
Methods

Animals
The Harvard Medical Area Standing Committee on Animals approved these studies. ROCK2 +/À mice were generated as previously described [33] and were on a C57BL/6 background. Gender-matched littermates were used as wild-type (WT) controls. OT-II and CD4-Cre mice were purchased from The Jackson Laboratories (Bar Harbor, ME, USA). ROCK2 flox/flox mice were generated as previously described [34] . ROCK2 CD4Cre mice were obtained by breeding ROCK2 flox/flox with CD4-Cre mice.
Protocol
Two cohorts of male mice were used. In the first cohort, four-to five-week-old WT and ROCK2 +/À mice were sensitized to ovalbumin (OVA, Grade V; Sigma-Aldrich Co., St. Louis, MO, USA) by i.p. injection with alum (Imject; Pierce-Thermo Fisher Scientific, Rockford, Il, USA) on days 0 and 14 as previously described [35, 36] (see Fig. 1a for schematic). On day 26, ROCK2 +/À mice received an i.v. injection of either saline or CD4 + cells from OT-II mice, as described below. WT mice received an injection of saline. On days 28 through 30, mice were challenged for 30 min with an aerosol of either PBS or 1% OVA, as previously described [13] .Forty eight hours after the last challenge, mice were anaesthetized and instrumented for the measurement of airway responsiveness. Mice were then killed with an overdose of sodium pentobarbital, blood was harvested by cardiac puncture for the preparation of serum, bronchoalveolar lavage (BAL) was performed, and the lungs were excised. One lung was fixed for subsequent histological assessment of mucous cell hyperplasia. The other lung was placed in RNAlater (Qiagen, Valencia, CA, USA) for subsequent preparation of RNA and qRT-PCR. In the second cohort (Fig. 1b) , the same protocol was used to sensitize, challenge, and evaluate ROCK2-flox/flox, CD4-Cre, and ROCK2CD4Cre mice, except that no injections were given on day 26, and no histology was performed. Instead, in these mice, one lung was used for flow cytometry to evaluate Th2 and Th17 cells.
CD4 cell preparation for adoptive transfer
To obtain CD4 + cells for adoptive transfer, spleens of OT-II mice were harvested, splenocytes isolated, and CD4 + lymphocytes enriched by negative selection using a pan antibody panel conjugated to magnetic beads (Dynabeads, Life Technologies, Carlsbad, CA, USA). The purity of the cell population was determined by flow cytometry after blocking of Fc receptor and surface staining for CD45-PE/Cy7 (30-F11), CD3-APC-Cy7 (17A2), and CD4-AF488 (GK1.5). All antibodies were purchased from Biolegend (San Diego, CA, USA). Using this process, we enriched the splenocyte from approximately 20% to over 70% CD4 + lymphocytes (Fig. S1 ).
Adoptive Transfer of CD4 + T cells from OT-II mice ROCK2 +/À mice were treated i.v. before the initiation of OVA challenge with either saline or 10 6 CD4 + cells from mice expressing a TCRab transgene for OVA peptide (OT-II mice). The number of CD4 cells was chosen based on its ability to restore the reduced BAL lymphocytes observed in allergen-challenged ROCK2 +/À mice to levels observed in similarly challenged WT mice (Fig. 2a) .
Bronchoalveolar Lavage
Bronchoalveolar lavage was performed and total and differential cell counts were evaluated as previously described [37] [38] [39] . BAL supernatants were stored at À80°C and subsequently analysed by ELISA for IL-5, IL-13, eotaxin (R&D Systems Inc., Minneapolis, MN, USA) and mast cell tryptase 1 (eBiosciences, San Diego, CA, USA). Serum was prepared and analysed for OVAspecific IgE by ELISA (Cayman, Ann Arbor, MI, USA). For the IL-5 ELISA, BAL fluid was concentrated 5-to 10-fold by centrifugation through a 3-kDa exclusion filter for 20 min as recommended by the vendor (Amicon Ultra-0.5 mL 3 kDa; Millipore, Billerica, MA, USA). Values expressed are those in the original BAL fluid.
Measurement of pulmonary mechanics and airway responsiveness
Mice were anaesthetized with xylazine (7 mg/kg) and sodium pentobarbital (50 mg/kg) and instrumented for the measurement of pulmonary mechanics and airway responsiveness to aerosolized methacholine by the forced oscillation technique, as previously described [39] .
Histopathologic assessment
Lung sections were used to quantify goblet cell hyperplasia by determining the number of PAS + cells in each airway. In cohort 1 (Fig. 1a) , after BAL, the right mainstem bronchus was clamped and the right lung was removed for subsequent preparation of RNA. The left lung was inflated in situ at 20 cm of water with 4% paraformaldehyde and then removed for paraffin embedding, sectioning, and staining for periodic acidSchiff (PAS) to evaluate goblet cell hyperplasia. Goblet cell hyperplasia was quantified by determining the number of PAS + cells in each airway (three to six airways per mouse) and dividing by the perimeter of the airway measured at the basal membrane. The images were captured with a high-definition AxioCam camera (Zeiss, Jena, Germany) coupled to an optical microscope (Olympus, Tokyo, Japan).
RNA extraction and real-time PCR
The left lung was harvested and RNA prepared and reverse-transcribed for real-time PCR as previously described [40] . Primers for murine Muc5ac and 18S ribosomal RNA were previously described [36] . Muc5ac mRNA abundance relative to 18S was calculated based on the DDCT method. For each set of primers, melting curve analysis yielded a single peak consistent with one PCR product.
Effect of ROCK inhibition on eotaxin release from human ASM cells
Primary human ASM cells from two different healthy donors (courtesy of Dr. Reynold Panettieri Jr., University of Pennsylvania) were grown until confluent, then washed with PBS, serum-deprived, and hormone-supplemented as previously described [41] . Twenty four hours later, cells were treated with the pan ROCK inhibitor Y-27632 (Calbiochem, San Diego, CA) or a ROCK2 specific inhibitor SR-3677 (Tocris, Bristol, UK) [42, 43] . Thirty minutes later, cells were challenged with IL-13 (eBiosciences) or with PBS. Twenty four hours later, cell supernatants were collected and assayed for eotaxin by ELISA (R&D Systems).
Flow cytometry
In mice in cohort 2 (Fig. 1b) , lung cell suspensions were obtained, stained for surface markers (CD45 and CD4) and intracellular IL-13 and IL-17, followed by flow cytometric analysis. Briefly, the lungs were excised, and the right lung was placed in medium containing monensin (Golgi Stop; BD Biosciences, Franklin Lakes, NJ, USA). Singlecell suspensions were prepared and stimulated with PMA and ionomycin as previously described [40] . Fixed and permeabilized cells had their Fc receptors blocked (FcX; Biolegend) and were stained as follows: CD45-PE/Cy7 (30F11), CD4-AF488 (GK1.5), CD3-APC/Cy7 (17A2), IL-17A-AF647 (TC11-18H10.1), IL-13-AF647 (eBio13A; Biolegend), or with isotype control (all antibodies from Biolegend unless noted). Cells were counted by flow +/À mice treated with saline than in WT treated with saline ( Fig. 2a-e) . In contrast, BAL MCPT1, a marker of mast cell degranulation, was unaffected by ROCK2 insufficiency (Fig. 2f) . Reductions in airway inflammation in ROCK2 +/À mice were not the result of effects of ROCK2 on allergic sensitization because there was no statistically significant difference in OVA-specific IgE in ROCK2 +/À vs. WT mice (Fig. S2 ) (note that all mice were OVA-sensitized).
Adoptive transfer of CD4 + cells from OT-II mice into ROCK2 +/À mice was used to reverse the effects of ROCK2 insufficiency on OVA-induced recruitment of lymphocytes to the lungs. Indeed, BAL lymphocytes were no longer different in WT mice vs. ROCK2 +/À mice that had received OVA-specific CD4 + cells (Fig. 2a) . Adoptive transfer also reversed the effects of ROCK2 insufficiency on BAL IL-13 and IL-5, and eosinophils: in ROCK2 +/À mice that received CD4 + T cells, OVA-induced increases in BAL IL-13, IL-5, and eosinophils were no longer different from WT mice (Fig. 2b-d) .
Bronchoalveolar lavage cells were also assessed in some additional OVA-sensitized and challenged WT mice that were administered OT-II cells i.v. before OVA challenge, and compared to cohort-matched WT mice administered i.v. saline before challenge. Whereas adoptive transfer of ROCK2-sufficient lymphocytes to ROCK2-insufficient mice increased both BAL lymphocytes and eosinophils (Fig. 2a,d) , the same adoptive transfer was without effect in WT mice that were already sufficient for ROCK2 (Fig. S3a,b) , indicating that in WT mice, simply increasing the number of circulating lymphocytes did not result in additional BAL lymphocytes, or any subsequent effects on BAL eosinophils. IL-13 is an important stimulus for release of eotaxin in allergic airways [41, 44, 45] . Nevertheless, despite the ability of adoptive transfer of CD4 + cells to restore BAL IL-13 to normal WT levels in ROCK2 +/À mice (Fig. 2b) , BAL eotaxin was not restored (Fig. 2e) . These data could be the result of ROCK2 acting within the cells that produce eotaxin. ASM cells produce eotaxin in response to IL-13 [41, 46] and are one important source of eotaxin in asthmatic airways [47, 48] . Consequently, we examined the impact of a chemical inhibitor of ROCK2 on IL-13-induced eotaxin release from human ASM cells. As previously described [41] , IL-13 (100 ng/mL) increased eotaxin release from ASM cells (Fig. 3) . Pre-treatment with the ROCK2-specific inhibitor, SR3677 [42] , caused a dose-dependent decrease in IL-13-stimulated eotaxin release (Fig. 3a) , indicating that ROCK2 is required for eotaxin release from ASM cells. Similar results were obtained with the pan ROCK inhibitor, Y-27632 [49] (Fig. 3b) . To our knowledge, this is first report of a role for ROCK2 in eotaxin release from any cell type. Hence, it is conceivable that ROCK2 also contributes to the release of eotaxin from other cell types in the airways that are important for producing this chemokine, for example airway epithelial cells.
OVA-specific CD4
+ cells rescue attenuated mucous cell hyperplasia in ROCK2 +/À mice ROCK2 insufficiency reduced the mucous cell hyperplasia that was induced by OVA challenge (Fig. 4 ): compared to OVA-challenged WT mice, OVA-challenged ROCK2 +/À mice treated with saline had fewer PAS + cells in the airway epithelium (Fig. 4a) and lower pulmonary Muc5a mRNA abundance (Fig. 4b) , consistent with previous observations [13] . ROCK2 acting within epithelial cells to promote the processes that allow for airway epithelial cell differentiation to goblet cells could account for this phenomenon. However, adoptive transfer of CD4 + cells from ROCK2-sufficient OT-II mice reversed the effects of ROCK2 insufficiency on mucous cell hyperplasia (Fig. 4) . IL-13 is known to promote mucous cell hyperplasia and Muc5ac mRNA expression [50] , and reduced BAL IL-13 in ROCK2 +/À was also reversed after adoptive transfer of ROCK2-sufficient CD4 + cells (Fig. 2b) , suggesting that ROCK2 within airway epithelial cells is not essential for mucous cell hyperplasia.
+ cells do not rescue attenuated OVAinduced AHR in ROCK2 +/À mice Compared to WT mice challenged with PBS, WT mice challenged with OVA developed AHR:
methacholine-induced changes in each of the pulmonary mechanical parameters examined (Rn (Newtonian resistance), G (tissue resistance), and H (tissue elastance)) were greater in OVA-challenged than in PBS-challenged WT mice (Fig. 5) . Airway responsiveness was significantly reduced in ROCK2 +/À vs. WT mice challenged with OVA and treated with saline (Fig 5) , indicating that ROCK2 is required for OVAinduced AHR, as previously described [13] . In contrast to the effects of adoptive transfer on allergic airway inflammation (Fig. 2) , we observed no effect of adoptive transfer of CD4 + cells on OVA-induced AHR in ROCK2 +/À mice: airway responsiveness was not different in OVA-challenged ROCK2 +/À mice treated with saline vs. those treated with CD4 + cells (Fig. 5) .
Genetic deletion of ROCK2 in CD4 + cells
The data from the experiments above using adoptive transfer of CD4 cells (Fig. 2) suggested that ROCK2 acting within CD4 + cells was required for OVAinduced eosinophil recruitment, Th2 cytokine production, and mucous hypersecretion, but not AHR. To confirm such a role for ROCK2, we genetically depleted ROCK2 specifically in CD4 + cells by crossing ROCK2 flox/flox mice with mice expressing Cre recombinase under control of a CD4 promoter (CD4-Cre mice). Interestingly, OVA-induced increases in BAL lymphocytes, and IL-13, were not different in ROCK2
CD4cre vs. control mice (ROCK2 flox/flox and CD4 Cre mice) (Fig. 6a,  b) , nor was there any difference in the number of (Fig. 6c) in ROCK2 CD4cre vs. ROCK2 flox/flox mice. Genetic deletion of ROCK2 in CD4 cells also failed to affect BAL eosinophils (Fig. 6d) and to prevent allergen-induced AHR (Fig. 6e) .
It has been previously established that ROCK2 is required for the induction of Th17 cells in response to other stimuli [51, 52] . Hence, to confirm functional ROCK2 depletion within CD4 + cells in the lungs of ROCK2 CD4cre mice, we examined pulmonary Th17 cells. Compared to ROCK2 flox/flox mice, pulmonary IL-17A + CD4 + cells were substantially reduced in both PBS-and OVA-challenged ROCK2 CD4cre mice (Fig. 6f ).
Discussion
Our data indicate an important role for ROCK2 in allergic airways disease: OVA-induced cellular inflammation, type 2 cytokine production, mucous hypersecretion, and AHR were each substantially reduced in ROCK2 +/À vs. WT mice treated with saline (Figs 2,4 and 5), consistent with previous reports [13, 17] . The pan ROCK inhibitors, fasudil and Y-27632, also attenuate these outcomes in allergen-challenged mice [16, 17, 53] . Together, the data indicate a key role for ROCK2 in allergen-induced eosinophil recruitment, mucous cell hyperplasia, and AHR. Data from this study allow us to begin to determine the cellular site of action of ROCK2 in mediating these events, as described below.
Administration of CD4 + cells from ROCK2-sufficient OT-II mice restored BAL lymphocytes and their type 2 cytokines, IL-13 and IL-5, in ROCK2 +/À mice (Fig. 2) . Administration of these CD4 + cells also restored eosinophilic inflammation and mucous cell hyperplasia (Figs 2 and 4), consistent with the known role for IL-5 as an eosinophil survival factor [54] and the requirement for IL-13 for allergen-induced mucous cell hyperplasia [45] . Nevertheless, genetically depleting ROCK2 only in CD4 + cells had no effect on OVA-induced increases in BAL lymphocytes, or associated changes in IL-13 expression or eosinophil migration (Fig. 6) . How can these observations be reconciled? First, we cannot rule out the possibility that the observed effects of adoptive transfer were the result not of CD4 + cells, but of some other spleen cells transferred with them, because the cells transferred were not 100% CD4 cells (Fig. S1) . Second, the transendothelial migration of lymphocytes from the blood into tissues occurs in a manner that reportedly involves ROCK-dependent signalling events in both the lymphocytes and the endothelial cells [6, 55] . As described above, we observed impaired OVAinduced lymphocyte recruitment to the lungs only when both endothelial cells and lymphocytes had impaired ROCK2 expression (data summarized in Table 1 . Thus, it may be that normal expression and function of ROCK2 in either lymphocytes or pulmonary vascular endothelial cells is sufficient for transmigration of lymphocytes into the lungs: although reduced compared to normal, lymphocyte/endothelial cell adhesion is still sufficiently strong in mice expressing normal ROCK2 in either cell type to permit normal lymphocyte transmigration (Table 1) . Additional experiments in endothelial cellspecific ROCK2 À/À mice will be required to address this possibility.
Others have reported that ROCK contributes to T cell migration and proliferation [13, [20] [21] [22] [23] . Hence, we were somewhat surprised by the lack of effect of CD4 + cell-specific ROCK2 deficiency on OVA-induced lymphocyte recruitment and IL-13 expression (Fig. 6) . However, the known effects of ROCK within lymphocytes [6, 13, [20] [21] [22] [23] are largely based on experiments with ROCK inhibitors like Y-27632, which block both ROCK1 and ROCK2. Taken together with our observations (Fig. 6) , the data suggest that effects of ROCK within lymphocytes are mediated by ROCK1 rather than by ROCK2.
ROCK2 also contributed to OVA-induced AHR (Fig. 5) . In mice, IL-13 is required for allergen-induced AHR [56] [57] [58] and BAL IL-13 was also reduced in ROCK2 +/À vs. WT mice challenged with OVA (Fig. 2b) . However, returning BAL IL-13 to normal WT levels by the administration of CD4 [59] . MLCP dephosphorylates MLC [59] . By inhibiting MLCP, ROCK prolongs MLC phosphorylation and promotes smooth muscle contraction. Consequently, ROCK inhibitors or genetic insufficiency in ROCK1 or ROCK2 attenuates contractile responses in tracheal rings stimulated with cholinergic agonists [60, 61] . Similarly, the ability of IL-17A to augment ROCK2 expression contributes to the ability of IL-17A to augment contractile responses of ASM [62] . The observation that ROCK2-specific inhibitors attenuate contractile agonist-induced force generation in cultured human ASM cells [63] also indicates that ROCK2 in particular can promote ASM contraction. Thus, following allergen challenge, ROCK2 acting within ASM cells likely contributes not only to eotaxin release but also to AHR. Experiments with smooth muscle-specific ROCK2-deficient mice will ultimately be needed to directly test this hypothesis.
Although we did not observe any significant attenuation of airway eosinophilia, BAL type 2 cytokines, or AHR in mice lacking ROCK2 only in CD4 cells (Fig. 6 ), Th17 cells were markedly reduced in these mice (Fig. 6f) . ROCK2 phosphorylates IRF4, a transcription factor required for the production of IL-17, and is required for the induction of Th17 cells [51] . Hence, our data ( Fig. 6f ) confirm functional depletion of ROCK2 within CD4 + cells in the lungs of these mice. This attenuation of Th17 cells without changes in the major features of allergic airways disease (Fig. 6) is consistent with data indicating that IL-17A is not required for allergic airways disease in this model [64] . The observation that ROCK2 CD4cre mice had marked reductions in Th17 cells is consistent with the observation that ROCK2-specific inhibitor, KD-025, attenuates the progression of collagen-induced arthritis in mice, a Th17-dependent process [52] . KD-025 also reduces IL-17 production in human T cells without affecting IFN-c production [52] . Together with our data indicating no effect of CD4 + -specific ROCK2 deficiency on IL-13 expression (Fig. 6) , the data also indicate that Th17 cells are more dependent upon ROCK2 than other CD4 + cells (Th1 and Th2). Whether ROCK2 plays a role in IL-17A expression by other cells, like cd T cells and innate lymphoid cells type 3 (ILC3), remains to be established.
In summary, our data indicate that ROCK2 is a potential therapeutic target for allergic asthma: allergeninduced inflammation, goblet cell hyperplasia, and AHR were each attenuated in ROCK2 +/À vs. WT mice. ROCK2 in CD4 + T cells does not appear to be required for allergic airways responses. Instead, ASM cells and endothelial cells necessary for transvascular migration of lymphocytes appear to be the primary ROCK2 effector cells contributing to allergic airways responses. The pan ROCK inhibitor, fasudil, is currently in clinical trials in the United States for targeting a number of diseases (see ClinicalTrials.gov NCT00120718, NCT00670202, NCT00498615), but it may not be feasible for the treatment of asthma because concurrent inhibition of both ROCK isoforms may produce undesirable effects such as hypotension [65] . However, selective ROCK2 inhibitors (e.g. KD-025) are also in development [52] . Greater understanding of the site and mechanism of ROCK2 may permit the use of ROCK2-selective inhibitors for reduction of the symptoms of allergic asthma when conventional asthma therapies have failed. Finally, current asthma treatment poorly controls mucous hypersecretion [66] , and targeting ROCK2 may be beneficial in decreasing the mucus hypersecretion in asthmatics.
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